Verve Therapeutics, Inc. (VERV) Financials
Stock symbol VERV is outdated, potentially delisted? Maybe it is available on other exchange?
VERV Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2025 | 614.2 million | 140.7 million |
| Dec. 31, 2024 | 647.4 million | 154.0 million |
| Sept. 30, 2024 | 663.9 million | 155.4 million |
| June 30, 2024 | 700.9 million | 154.8 million |
VERV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2025 | -29.1 million | 11.2 million |
| Dec. 31, 2024 | -42.2 million | 10.4 million |
| Sept. 30, 2024 | -40.5 million | 10.8 million |
| June 30, 2024 | -35.1 million | 11.6 million |
VERV Net Income
No data available :(
VERV Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2025 | 497.1 million | 58.1 million | 68.6 million |
| Dec. 31, 2024 | 524.3 million | 59.5 million | 70.0 million |
| Sept. 30, 2024 | 539.9 million | 60.9 million | 71.3 million |
| June 30, 2024 | 575.9 million | 62.2 million | 72.5 million |
VERV Shares Outstanding
VERV Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2025 | 1.2 million | 54.5 million | 15.2 million | - |
| Dec. 31, 2024 | 1.4 million | 55.0 million | 14.1 million | - |
| Sept. 30, 2024 | 936000 | 49.9 million | 13.8 million | - |
| June 30, 2024 | 980000 | 51.0 million | 14.5 million | -1.7 million |
VERV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2025 | 33.0 million | - |
| Dec. 31, 2024 | 13.1 million | 1.7 million |
| Sept. 30, 2024 | 6.9 million | 1.8 million |
| June 30, 2024 | 6.7 million | 1.7 million |
VERV
Price: $11.13
52 week price:
Earnings Per Share: -2.11 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 434163
Market Capitalization: 994.0 million